Zacks Research Cuts Q1 2023 EPS Estimates for DaVita

March 19, 2023

Trending News 🌧️

DAVITA ($NYSE:DVA): Zacks Research has recently announced that they are reducing their Q1 2023 earnings per share (EPS) estimates for DaVita Inc., a leading healthcare provider. This is due to a variety of factors, including significant losses in the company’s Medicare Advantage business, as well as lower volumes in the dialysis and oncology services segment. DaVita Inc. has been dealing with various issues, such as a recent legal settlement and continued uncertainty in the healthcare industry due to the ongoing pandemic. These issues have all contributed to the reduced Q1 2023 EPS estimates from Zacks Research. Additionally, DaVita Inc. has announced several strategic initiatives to reduce costs and increase efficiency, which could help to offset some of these losses.

However, many analysts believe that the company is taking the right steps to address its challenges and will be well-positioned to succeed in the long term. Investors should closely monitor DaVita Inc.’s performance over the coming quarters and make informed decisions about their investments.

Price History

On Monday, DaVita Inc. experienced a slight uptick in its stock price, with an opening at $74.2 and closing at $75.1 – a 0.5% increase from the previous closing price of 74.7. However, despite this minor gain, the news surrounding DaVita Inc. is mostly negative at the moment. This suggests that DaVita Inc.’s future performance is uncertain and investors should exercise caution when considering the company’s stock. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Davita Inc. More…

    Total Revenues Net Income Net Margin
    11.61k 560.4 4.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Davita Inc. More…

    Operations Investing Financing
    1.56k -630.35 -1.12k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Davita Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    16.93k 14.7k 5.91
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Davita Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.6% -9.2% 11.4%
    FCF Margin ROE ROA
    8.3% 132.9% 4.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently completed our analysis of DAVITA INC‘s wellbeing. After going through financial and business aspects, our Risk Rating showed DAVITA INC was a low risk investment. We also detected two risk warnings in the balance sheet and cashflow statement of DAVITA INC, which may be of concern to investors. To find out more, be sure to register on and you can get more details. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the dialysis industry, DaVita Inc. competes with Acadia Healthcare Co Inc, Fresenius Medical Care AG & Co. KGaA, Medical Facilities Corp, and other companies. The company has a network of 2,664 outpatient dialysis centers in the United States that serve approximately 198,000 patients with end-stage renal disease.

    – Acadia Healthcare Co Inc ($NASDAQ:ACHC)

    Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services. It operates a network of behavioral healthcare facilities in the United States, Puerto Rico, and the United Kingdom. The company offers inpatient psychiatric and substance abuse services, residential treatment, outpatient behavioral health services, and specialty behavioral healthcare services.

    – Fresenius Medical Care AG & Co. KGaA ($LTS:0H9X)

    Fresenius Medical Care AG & Co. KGaA, a renal care company, provides products and services for patients with renal diseases worldwide. The company’s products and services include dialysis machines, dialyzers, and related disposable products, as well as renal pharmaceuticals. It also offers clinical laboratory testing services. The company was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

    – Medical Facilities Corp ($TSX:DR)

    Medical Facilities Corporation is a leading operator of specialty surgical hospitals and ancillary services in the United States. The company owns and operates seven specialty surgical hospitals, one surgical hospital, and three surgical facilities located in Arkansas, Illinois, Louisiana, Mississippi, Oklahoma, and Texas. Medical Facilities Corporation’s hospitals offer a broad range of services, including general surgery, cardiovascular surgery, orthopedic surgery, pain management, gastroenterology, urology, and otolaryngology. The company’s hospitals are accredited by the Joint Commission on Accreditation of Healthcare Organizations and are licensed by the respective state Departments of Health.


    Investing analysis of DaVita Inc (NYSE: DVA) has been unfavorable recently due to lower than expected earnings in the first quarter of 2023. According to Zacks Research, the company’s earnings per share (EPS) estimates were cut, resulting in a negative outlook for the current year. Investors are advised to closely monitor the company’s financials and look for signs of improvement in the coming quarters.

    Additionally, potential investors should be aware of the company’s competitors and the potential risks associated with investing in the healthcare industry. With this information, investors may be able to make an informed decision about their investments in DaVita Inc.

    Recent Posts

    Leave a Comment